Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.

Scholz M, Ackermann M, Engel C, Emmrich F, Loeffler M, Kamprad M.

Cell Prolif. 2009 Dec;42(6):813-22. doi: 10.1111/j.1365-2184.2009.00638.x. Epub 2009 Aug 17.

PMID:
19689472
[PubMed - indexed for MEDLINE]
2.

Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.

Scholz M, Engel C, Apt D, Sankar SL, Goldstein E, Loeffler M.

Cell Prolif. 2009 Dec;42(6):823-37. doi: 10.1111/j.1365-2184.2009.00641.x. Epub 2009 Sep 24.

PMID:
19780759
[PubMed - indexed for MEDLINE]
3.

Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.

Scholz M, Schirm S, Wetzler M, Engel C, Loeffler M.

Theor Biol Med Model. 2012 Jul 30;9:32. doi: 10.1186/1742-4682-9-32.

PMID:
22846180
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.

Scholz M, Ackermann M, Emmrich F, Loeffler M, Kamprad M.

Biologics. 2009;3:27-37. Epub 2009 Jul 13.

PMID:
19707393
[PubMed]
Free PMC Article
5.

Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model.

Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA.

Pharmacol Res. 2004 Jul;50(1):55-8.

PMID:
15082029
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.

Lyman G, Lalla A, Barron R, Dubois RW.

Curr Med Res Opin. 2009 Feb;25(2):401-11. doi: 10.1185/03007990802636817 .

PMID:
19192985
[PubMed - indexed for MEDLINE]
7.

The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

Molineux G.

Curr Pharm Des. 2004;10(11):1235-44. Review.

PMID:
15078138
[PubMed - indexed for MEDLINE]
8.

Pharmacokinetics of pegfilgrastim.

Zamboni WC.

Pharmacotherapy. 2003 Aug;23(8 Pt 2):9S-14S. Review.

PMID:
12921217
[PubMed - indexed for MEDLINE]
9.

Mathematical model for G-CSF administration after chemotherapy.

Foley C, Mackey MC.

J Theor Biol. 2009 Mar 7;257(1):27-44. doi: 10.1016/j.jtbi.2008.09.043. Epub 2008 Nov 1.

PMID:
19007795
[PubMed - indexed for MEDLINE]
10.

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

Ng R, Green MD.

Expert Rev Anticancer Ther. 2005 Aug;5(4):585-90. Review.

PMID:
16111460
[PubMed - indexed for MEDLINE]
11.

Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

Wiczling P, Lowe P, Pigeolet E, L├╝dicke F, Balser S, Krzyzanski W.

Clin Pharmacokinet. 2009;48(12):817-26. doi: 10.2165/11318090-000000000-00000.

PMID:
19902989
[PubMed - indexed for MEDLINE]
12.

Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques.

Farese AM, Yang BB, Roskos L, Stead RB, MacVittie TJ.

Bone Marrow Transplant. 2003 Aug;32(4):399-404.

PMID:
12900776
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB.

J Clin Pharmacol. 2006 Jul;46(7):747-57.

PMID:
16809800
[PubMed - indexed for MEDLINE]
14.

Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy.

Morishita M, Leonard RC.

Expert Opin Biol Ther. 2008 Jul;8(7):993-1001. doi: 10.1517/14712598.8.7.993 . Review.

PMID:
18549328
[PubMed - indexed for MEDLINE]
15.

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH.

Value Health. 2008 Mar-Apr;11(2):172-9. doi: 10.1111/j.1524-4733.2007.00242.x.

PMID:
18380630
[PubMed - indexed for MEDLINE]
16.

Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim.

Ribeiro D, Veldwijk MR, Benner A, Laufs S, Wenz F, Ho AD, Fruehauf S.

Transfusion. 2007 Jun;47(6):969-80.

PMID:
17524085
[PubMed - indexed for MEDLINE]
17.

Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.

Renwick W, Pettengell R, Green M.

BioDrugs. 2009;23(3):175-86. doi: 10.2165/00063030-200923030-00004. Review.

PMID:
19627169
[PubMed - indexed for MEDLINE]
18.

A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.

Schirm S, Engel C, Loeffler M, Scholz M.

Theor Biol Med Model. 2014 May 26;11:24. doi: 10.1186/1742-4682-11-24.

PMID:
24886056
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.

Lyman GH, Lalla A, Barron RL, Dubois RW.

Clin Ther. 2009 May;31(5):1092-104. doi: 10.1016/j.clinthera.2009.05.003.

PMID:
19539110
[PubMed - indexed for MEDLINE]
20.

Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.

Shochat E, Rom-Kedar V.

Clin Cancer Res. 2008 Oct 15;14(20):6354-63. doi: 10.1158/1078-0432.CCR-08-0807.

PMID:
18927273
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk